

BASTIDE obtains an extended license to operate in Canada in the Respiratory Care segment

Sale of French stomatherapy subsidiary CICA PLUS

Caissargues, January 8, 2025 – Groupe Bastide, one of Europe's leading players in home healthcare services, announces its newly extended license to operate in the field of respiratory care in British Columbia, Canada, and the sale of its French subsidiary CICA PLUS, specialized in stomatherapy.

Confirmation of organic growth potential in Canada in the Respiratory Care Segment

Present on the Canadian home respiratory care market since the acquisition of Medpro Respiratory Care in 2022, Bastide announces an extension of its subsidiary's operating license in the province of British Columbia. **This extended license represents potential full-year revenue of C\$5 million (€3.4 million).**

Through its subsidiary Medpro Respiratory Care, Bastide offers a wide range of respiratory products and services covering the oxygen therapy, non-invasive ventilation and sleep apnea segments in the provinces of British Columbia, Alberta and Ontario. This new extended license illustrates Bastide's organic growth potential in Canada.

Sale of French subsidiary CICA PLUS

As part of its strategy of divesting assets with low organic growth and/or additional value creation potential, Bastide announces the sale of its French subsidiary CICA PLUS, specialized in chronic wound care services. CICA PLUS achieved revenue of €3.4 million in 2023-2024 with negative EBITDA. The company will be deconsolidated from the group accounts as from October 1, 2024.

Groupe Bastide is continuing to analyze its portfolio of activities and potential assets for disposal, which will contribute to its priority objective of reducing debt and improving its leverage ratio.

NEXT PUBLICATION:

Half-yearly 2024-2025 revenue on Thursday, February 13, 2025 after the close of trading.



About Groupe Bastide Le Confort Médical

Created in 1977 by Guy Bastide, Groupe Bastide is a leading European provider of home healthcare services. Present in eight countries, Bastide develops a permanent quality approach and is committed to providing medical devices and associated services that best meet patients' needs in key health areas: diabetes, nutrition, infusion, respiratory care, stomatherapy and urology. Bastide is listed on Euronext Paris (ISIN: FR0000035370, Reuters BATD.PA, - Bloomberg BLC: FP).

CONTACTS

Groupe Bastide

Vincent Bastide/Olivier Jourdanney
T. +33 (0)4 66 38 68 08
www.bastide-groupe.fr

Actus Finance

Analyst-Investor
Hélène de Watteville
T. +33 (0)1 53 67 36 33

Press-Média
Déborah Schwartz
T. +33 (0)1 53 67 36 35

